Bausch + Lomb Releases 2025 Sustainability Impact Report

• The most recent release (April 22, 2026) is a 2025 Sustainability Impact Report detailing "The Broader Perspective" framework.
• Key commitments include Net Zero greenhouse gas emissions by 2050 and specific waste reduction targets like 10% power demand decrease at the Rochester site.
• The report highlights progress in packaging weight reduction for contact lenses and digital transitions to reduce paper waste.
• Previous news (April 8, April 7) confirms FDA clearance for Bi-Blade+ vitrectomy cutter and European launch of enVista Envy IOLs.
• Financial context from February 2026 earnings shows revenue growth ($5.1B FY25) but widened GAAP net loss ($360M).
• Refinancing news (December 2025) indicates a $2.8B term loan extension to 2031 with reduced interest margins.

• The sustainability report is expected corporate governance activity and does not introduce new financial data or product breakthroughs.
• It reinforces existing commitments made during the Investor Day (November 2025) regarding ESG metrics but lacks immediate revenue implications.
• Given the company's focus on operational leverage and margin expansion, this news supports long-term risk management rather than short-term stock price appreciation.
• The material impact is neutral to slightly positive for reputation but does not alter the fundamental valuation drivers (revenue growth vs. GAAP losses).
• No new strategic investors or major capital raises are announced in this release; financing remains stable with the December refinancing.

• Bausch + Lomb operates in Vision Care, Surgical, and Pharmaceuticals segments with a focus on eye health solutions.
• Flagship projects include the enVista platform (premium intraocular lenses) and MIEBO (dry-eye pharmaceutical).
• The Elios laser system for glaucoma treatment is a key development asset pending US FDA approval for launch in H2 2026.
• The company recently separated from Bausch Health Companies Inc., aiming to operate as an independent entity with streamlined operations.
• Revenue growth is driven by the dry-eye portfolio and premium IOLs, though GAAP profitability remains challenged by restructuring and tax provisions.